Biomarker study in amyotrophic lateral sclerosis (ALS) for early detection of misfolded TDP-43 through nano-quic assays
Active Grant Awarded
- Award ID
- R61NS149366
- Recipient
-
Regents Of The University Of Minnesota UEI KABJZBBJ4B54
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,782,882
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date 7% complete
- Place of performance
- Minneapolis, MN 55455, USA
Award details come from USAspending.gov.
About this award
Department of Health and Human Services, National Institutes of Health, National Institute of Neurological Disorders and Stroke awarded Regents of the University of Minnesota $1,782,882 on September 9, 2026, under Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), Grant R61NS149366. The full $1,782,882 is obligated. The award funds a two-stage biomarker study for early detection of misfolded TDP-43 in amyotrophic lateral sclerosis (ALS) using NANO-QUIC assays. Stage one confirms the assay can reliably identify the protein in brain tissue from people who died of ALS and in spinal fluid from people with ALS. It then tests blood and, if necessary, nasal swabs to distinguish people with ALS from healthy individuals and from people with other conditions causing similar symptoms, optimizing the test with established laboratory tools. If stage one succeeds, stage two conducts larger-scale testing on new samples from people recently evaluated for ALS symptoms and from healthy individuals. Its results will determine whether the tests are ready for broader testing and possible approval as a routine clinical test. The award runs from September 9, 2026 to an ultimate completion date of July 31, 2029, with work performed in Minneapolis, Minnesota (55455). The recipient does business as the Office of Sponsored Projects Administration. The source identifies no sub-recipients on this award.
Description
- Abstract
- Amyotrophic lateral sclerosis (ALS) is a neurological condition that causes progressive weakness, disability, and death. On average, people wait 12 months from the time they develop symptoms until they are diagnosed. Because survival in ALS is only 3-5 years on average, many people do not receive the diagnosis until well into the disease process. This "diagnostic delay" results in delays in treatment and research. As better treatments are developed for ALS, IT will become all the more crucial to diagnose the disease early and more easily. The misfolded TDP-43 protein has emerged as a key feature in most patients with ALS, thus, early detection of misfolded TDP-43 can accelerate diagnosis, treatment, and enrollment in clinical research. This project will test whether a new diagnostic process called nano-quic can diagnose ALS early and easily, and whether IT can also be used to confirm ALS when the diagnosis remains unclear after standard testing. We will begin by confirming that we can identify this protein reliably in brain tissue from people who died due to ALS, and in spinal fluid in people with ALS. We will also test blood and, if necessary, swabs from the nose, to see if we can distinguish people with ALS from healthy individuals and from people with other conditions that cause similar symptoms. Using established tools in our laboratory, we will optimize the test to make IT as reliable as possible. This is a two stage project. If we are successful at developing these diagnostic tests in the first phase, we will proceed to larger-scale testing in a new set of samples from people recently evaluated for symptoms of ALS as well, again, as healthy individuals. The results of this second stage will determine whether these tests are ready for broader testing and possible approval as a routine clinical test. This research is significant as IT seeks to develop a simple, affordable way to determine whether a person may have ALS to accelerate diagnosis both of ALS and of other conditions that may mimic ALS. By doing so, we hope to enhance the potential benefits of existing and experimental therapeutics for ALS patients, providing a greater opportunity for successful treatment outcomes. Our project has the potential to make a substantial impact on clinical trial design and patient outcomes in ALS.
Quick answers
Who received award R61NS149366?
R61NS149366 was awarded to Regents Of The University Of Minnesota by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 9, 2026.
How much is award R61NS149366 worth?
$1,782,882 has been obligated on R61NS149366.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award